Henry Schein (NASDAQ:HSIC – Get Free Report) and RHÖN-KLINIKUM Aktiengesellschaft (OTCMKTS:RKAGY – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
Institutional & Insider Ownership
96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 0.2% of RHÖN-KLINIKUM Aktiengesellschaft shares are owned by institutional investors. 0.9% of Henry Schein shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Henry Schein and RHÖN-KLINIKUM Aktiengesellschaft, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Henry Schein | 1 | 6 | 8 | 0 | 2.47 |
| RHÖN-KLINIKUM Aktiengesellschaft | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Henry Schein and RHÖN-KLINIKUM Aktiengesellschaft’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Henry Schein | 2.96% | 15.97% | 5.56% |
| RHÖN-KLINIKUM Aktiengesellschaft | N/A | N/A | N/A |
Valuation & Earnings
This table compares Henry Schein and RHÖN-KLINIKUM Aktiengesellschaft”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Henry Schein | $13.18 billion | 0.75 | $398.00 million | $3.43 | 26.03 |
| RHÖN-KLINIKUM Aktiengesellschaft | N/A | N/A | N/A | $4.50 | 1.81 |
Henry Schein has higher revenue and earnings than RHÖN-KLINIKUM Aktiengesellschaft. RHÖN-KLINIKUM Aktiengesellschaft is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.
Summary
Henry Schein beats RHÖN-KLINIKUM Aktiengesellschaft on 10 of the 11 factors compared between the two stocks.
About Henry Schein
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
About RHÖN-KLINIKUM Aktiengesellschaft
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. It also operates acute hospitals, medical care centers, and rehabilitation hospitals. The company was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
